Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors

Figure 4 79 year old female with well-differentiated neuroendocrine tumors, unknown primary, treated with a complete ¹⁷⁷Lu-DOTATATE regimen showing mild response. ¹⁷⁷Ga-DOTATATE positron emission tomography (PET) computed tomography transaxial fusion and whole body projection PET pre-therapy and post-therapy. A: Pre-therapy; B: Post-therapy. (A; top) Sternal osseous metastases are partially improved (red arrow; B top), and a mediastinal node is resolving (red arrow; paratracheal). (Bottom row) Dominant pelvic nodal mass (A; white arrow) has decreased (B; white arrow) in size 3.3 × 2.1 (previously 3.7 × 2.6), and uptake SUVmax 39.6 (previously 46.8).